Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SGMT

+ Watchlist+ Portfolio

Sagimet Biosciences Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$9.85
52-Week Range
$4.50 – $11.45
Market Cap
$727.27M
P/E (TTM)
—
EPS (TTM)
-1.18
Dividend Yield
0.00%
Advanced Metrics
Price/Book
2.61
PEG Ratio
—
Return on Equity
-29.50%
Return on Assets
-18.23%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
6.34
Debt/Equity
0.01
Total Debt
$2.02M
Free Cash Flow
$-479.38K
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$487.15M

Market Snapshot

About

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis and other metabolic diseases. The company uses novel therapeutic approaches targeting fatty acid metabolism. Sagimet is advancing multiple drug candidates through clinical trials.